| Name | Title | Contact Details |
|---|
Danville Regional Health System is a Danville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ambient Clinical Analytics is the creator of a software platform designed for data assimilation, communication and analytics. It is based on decision support tools initially deployed in the intensive care unit (ICU) or emergency department of hospitals. Our software consists of algorithms that mine data from electronic medical records (EMR). It then presents that data to the physicians and nurses so they may facilitate real-time clinical decision making and care delivery. These products are positioned as add on applications that are designed to easily integrate with the current major EMR providers. The highly fragmented global Healthcare IT and EMR market is expected to grow by 15% to $10 billion by 2015. Ambient believes there is a significant opportunity in this growing market to implement analytics based dashboard tools to reduce errors and improve efficiency. Our goal is supported by a $16 million CMS grant to deploy Ambient’s AWARE program in 3 hospitals starting September 2013. This software platform can be used in any data intensive hospital unit and is the perfect combination of “Big Data” and “Analytics”. Our analytical tools and suggested care checklists are unique to the current healthcare IT market. Ambient Clinical Analytics is supported financially by software license fees, SaaS, Cloud, and system integration revenue.
Hatten Holdings is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orexigen`s commitment to patients is reflected in all that we do: we are a company driven by the knowledge that our work is important and the desire to make a difference. Orexigen offers prospective employees exciting challenges` unique opportunities for career growth` and a fast-paced environment that emphasizes innovation and achievement.
Cellenkos is an early stage clinical biotechnology company that focuses on cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory conditions. Cellenkos is founded on the technologies arising from the laboratory investigations of Simrit Parmar, M.D. Cellenkos` lead product CK0801 delivers clinically meaningful doses of allogeneic cord blood T-regulatory cells to overcome immune dysfunction.